Quick answer: July's median new-home price fell to $393,800, but the average rose to $508,800 — up 5.4% year over year. The median dropped because the sales mix shifted down-market (the $300–400K band went from 28% to 34% of sales), not because prices fell in the $500K+ range where most physicians shop. New-home supply is genuinely loose at 9.6 months versus 4.6 for existing homes, so builder concessions are real — but they usually require the builder's preferred lender, which means giving up your physician mortgage.
If you are relocating for a job this fall, you have probably seen the headlines from this week: new-home sales fell 10.5% in July, inventory hit 9.6 months, and the median new-home price dropped to $393,800 — the lowest since 2021.
Read quickly, that sounds like builders are capitulating and it is finally a buyer's market. Read carefully, the same Census release says something more specific and more useful: builders are under real pressure, but the price relief is concentrated in a price band most physicians never shop in. And there is a second market — resale — where almost none of this is happening at all.
Here is what the data actually supports, and what it means for the loan you choose.
The one number that is statistically real
The Census Bureau publishes confidence intervals with every release, and this month they matter more than usual. A 90% confidence interval that contains zero means the change cannot be distinguished from no change at all.
- New-home sales, −10.5% from June: confidence interval ±14.0. Not significant.
- New-home sales, −6.3% from a year ago: ±19.6. Not significant.
- Months' supply, up from 8.5 to 9.6: ±21.3. Not significant.
- Median price, −2.3% from June: ±7.4. Not significant.
- Inventory, 488,000 homes, +1.9% from June: ±1.2. Significant.
The only headline change that clears the statistical bar is inventory rising. The June base was also revised, which is part of why the one-month drop looks so dramatic. So the "sales cliff" framing running everywhere this week rests on a number that may be noise.
What is not noise is the level: 9.6 months of supply. Four to six months is roughly balance. Builders are carrying close to double what the current sales pace absorbs, and finished homes are sitting longer — the median new home now waits 3.2 months on the market after completion, up from 2.6 a year ago. That is genuine builder pressure, and it is why concessions are where they are.
The mix shift almost nobody reported
Now the part that changes the decision for this audience.
The median new-home price fell to $393,800. The average new-home price rose to $508,800 — up 4.1% from June and up 5.4% from a year ago. Those two numbers moving in opposite directions is the signature of a mix shift, not broad price relief.
The Census price-distribution table confirms it. Homes sold in the $300,000–$400,000 band went from 28% of all new-home sales in June to 34% in July. The $500,000–$600,000 band fell from 14% to 10%.
In plain terms: more entry-level homes closed and fewer mid-tier ones did. That pulls the median down mechanically, without any individual builder cutting a price. The upper half of the market — where the average price lives, and where an attending buying near a hospital in a metro area is usually shopping — went up year over year.
If you are looking at $600,000 and you read "new-home prices hit a five-year low," the release does not say what you think it says.
Two markets, and your loan works better in one of them
The other thing the July data makes clear is that "the housing market" is not one market right now.
| | New homes (July) | Existing homes (July) | |---|---|---| | Months' supply | 9.6 | 4.6 | | Median price | $393,800, −0.9% year over year | $434,100, +2.0% year over year |
Existing-home supply was 4.6 months — unchanged from June and unchanged from a year ago — and the median resale price has now risen year over year for 37 consecutive months. Resale sellers have not lost their leverage. Builders have.
That asymmetry is the whole story for a buyer with a physician mortgage, because builder leverage gets spent in a very specific way.
Where the builder's concession actually goes
Roughly 63% of builders reported using sales incentives in July — the sixteenth consecutive month at 60% or higher — and about 37% reported cutting prices, averaging around 6%. The most common incentives are mortgage-rate buydowns, closing-cost assistance, and design-center upgrades.
The catch is delivery. Those incentives are almost always routed through the builder's own affiliated or preferred lender. A physician mortgage is a portfolio product from a different lender entirely. In most cases you cannot stack them, which turns a marketing offer into a real fork:
- Take the builder's lender. You get the buydown and the closing-cost credit, but you are underwritten conventionally: a down payment, likely PMI, and your full student-loan payment counted in DTI. What you are buying is a lower monthly payment.
- Take the physician mortgage. Little or nothing down, no PMI, and student debt treated on the program's terms. What you are buying is approval and cash retention.
Neither is automatically right. But with builder concessions at a sixteen-month high and inventory at 9.6 months, the builder side of that trade is richer than it has been at any point in this cycle — which means the comparison deserves to be run properly rather than assumed. Our guide to how builders' preferred lenders actually work walks through the mechanics, including why a $10,000 credit is rarely free.
What has not changed: rates
One caution, because it is being widely misstated. Mortgage rates are not falling. Freddie Mac's survey put the 30-year fixed at 6.66% on August 27, up a basis point on the week and about 10 basis points higher than a year ago.
Several housing outlooks still circulating from earlier this year predicted lower rates and rising supply for 2026. Half of that has happened — supply is up sharply, but only in new construction. Rates are not lower. If a projection you are relying on was written on both assumptions, it is worth re-checking.
How to use this
If you are a physician buying in the next few months:
- Check the price band, not the headline. Pull the median for new construction in your specific metro and your specific price range. The national median tells you about a market segment you may not be in.
- Decide which market you are shopping. New construction gives you inventory, negotiating room, and concessions. Resale gives you location and established neighborhoods at a higher price with less leverage. They are not interchangeable this year.
- Price the fork, don't assume it. Get a written quote from the builder's preferred lender and from a physician-loan lender, then compare total cash to close, monthly payment, and — critically — whether each one approves you at the price you want. A buydown you cannot qualify for is not a deal.
- Ask how long the house has been finished. With finished homes averaging over three months on the market, a spec home that has been sitting is where a builder's flexibility is most real.
The buyer's market in new construction is real. Just make sure it is a buyer's market at your price.
This article is for educational purposes only. MedPharmaConnect is not a lender and does not originate mortgages. Market data is as of the July 2026 reporting period; figures are revised regularly.
MedPharmaConnect is an educational resource, not a lender. Always verify program details, current rates, and eligibility with licensed mortgage professionals.